


Oncology
2024-04-10

HER2 overexpression is common in gastric and gastroesophageal cancer, emphasizing the need to target HER2 in treatment. Gempharmatech offers PDX gastric cancer models with varying HER2 levels, identified through immunohistochemistry. These models, exemplified by one with heterogeneous HER2 expression, provide detailed insights into drug responses, particularly highlighting the efficacy of Trastuzumab deruxtecan, contributing to precision medicine in HER2-targeted therapy development.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
